| Regulatory
Matters |
| • |
Antidepressants |
| • |
Botulinum
toxin Type A and Botulinum toxin Type B |
| • |
Clopidogrel |
| • |
Codeine
and dihydrocodeine-containing medicines |
| • |
Colchicine |
| • |
Etanercept |
| • |
Etravirine |
| • |
Fosamprenavir |
| • |
Leukotriene
inhibitors: montelukast, zafirlukast and zileuton |
| • |
Mycophenolic
acid |
| • |
Promethazine
hydrochloride injection |
| • |
Sodium
phosphate products |
| • |
Tumour
necrosis factor blockers |
|
Safety of Medicines |
| • |
Allopurinol |
| • |
Duloxetine |
| • |
Isotretinoin |
| • |
Leflunomide |
| • |
Methaemoglobinaemia |
| • |
Natalizumab |
| • |
Nitrous
oxide |
| • |
Omalizumab |
| • |
Orlistat |
| • |
Oseltamivir
phosphate |
| • |
Warfarin
and aspirin combination |
| Feature |
| • |
Pilot
medication error system by the New Zealand Pharmacovigilance Centre |
| • |
Paracetamol
and acute generalized exanthematous pustulosis |
| • |
Summary
of the information published on the MPA website (Oct 29, 2009) regarding
adverse drug reaction reports in Sweden with Pandemrix – the
influenza A (H1N1) vaccine |
